
PharmaSGP Holding SE
PSG | F
Overview
Corporate Details
- ISIN(s):
- DE000A2P4LJ5
- LEI:
- 3912005CZ12PVVCIPT91
- Country:
- Germany
- Address:
- Lochhamer Schlag 1, 82166 Gräfelfing
- Website:
- https://pharmasgp.com/english/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
harmaSGP is a pharmaceutical company with a broad portfolio of leading, over-the-counter (OTC) drugs and other healthcare products. Our drugs are based on natural pharmaceutical active ingredients with documented efficacy and have virtually no known side effects. With our pharmacy-exclusive products, we have trusted brands in many relevant chronic indications that are leaders in their respective categories. The herbal-medicine Baldriparan®, is the leading OTC brand in Germany for natural valerian sleep aids. With the brands RubaXX® for rheumatic pain and Restaxil® for neuralgic pain (nerve pain), we are also the market leader for systemic, chemical-free OTC pain relievers. In addition, the products against sexual weakness, which are marketed under the brands DESEO® and NERADIN®, are the leading chemical-free products in their category in Germany. Since the launch of the first product from the current portfolio in Germany in 2012, we have successfully exported our business.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-06-26 12:39 |
AGM Report
PharmaSGP Holding SE holds 2025 Annual General Meeting
|
English | 9.2 KB | |
2025-06-18 17:29 |
Major Shareholding Notification
PharmaSGP SE plans to redeem own shares conditions for squeeze-out under conve…
|
English | 7.6 KB | |
2025-06-11 11:15 |
Directors' Dealings
PharmaSGP Holding SE: FUTRUE GmbH, Interest-sustaining purchase order for up to…
|
English | 6.6 KB | |
2025-06-10 08:42 |
Delisting Announcement
PharmaSGP Holding SE: Conclusion of a delisting agreement and announcement of a…
|
English | 13.5 KB | |
2025-05-28 00:00 |
Regulatory News Service
Q1 statement / Q1 financial report 2025
|
English | 517.8 KB | |
2025-05-19 15:01 |
Directors' Dealings
PharmaSGP Holding SE: FUTRUE GmbH, buy
|
English | 6.0 KB | |
2025-05-16 07:30 |
Earnings Release
PharmaSGP continues its growth course in 2025
|
English | 15.9 KB | |
2025-05-14 15:05 |
General Meeting Notice
PharmaSGP Holding SE: Bekanntmachung der Einberufung zur Hauptversammlung am 25…
|
German | 127.8 KB | |
2025-05-09 11:00 |
Declaration of Voting Results & Voting Rights Announcements
|
English | 12.1 KB | |
2025-04-30 00:00 |
Takeover Announcement Report
Annual financial report 2024
|
English | 22.7 MB | |
2025-04-23 14:30 |
Report Publication Announcement
|
English | 4.4 KB | |
2025-04-15 07:30 |
Earnings Release
PharmaSGP with significant increase in revenues and EBITDA in 2024
|
English | 16.7 KB | |
2024-11-29 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2024
|
English | 517.2 KB | |
2024-11-28 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2024
|
English | 517.2 KB | |
2024-11-28 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2024
|
English | 517.2 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2024-11-25 | FUTRUE GmbH | Close relation | Buy | None | 12,145,250.00 EUR |
2022-10-05 | MMI Leisure & Capital Management GmbH | Close relation | Buy | None | 125,383.20 EUR |
2022-10-05 | Hillen, Ingo | Board | Buy | None | 1,048.00 EUR |
2022-10-05 | MMI Leisure & Capital Management GmbH | Close relation | Buy | None | 26.60 EUR |
2022-05-30 | Wittig, Dr. Thomas | Supervisory board | Buy | None | 138,953.80 EUR |
2022-05-30 | Schröter, Jasmin | Close relation | Buy | None | 119,660.00 EUR |
2022-05-30 | Simon-Schröter, Dr. Wolfram | Other | Buy | None | 10,040.00 EUR |
2022-04-25 | FUTRUE GmbH | Close relation | Buy | None | 208,180.53 EUR |
2022-04-25 | MMI Leisure & Capital Management GmbH | Close relation | Sell | None | 197,193.60 EUR |
2022-04-25 | Bloching, Prof. Dr. Micha | Supervisory board | Sell | None | 171,825.00 EUR |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
![]() |
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
![]() |
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
Alma Yesodot Ltd. | Israel | KVSR | ||
![]() |
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
Ananda Pharma Plc | United Kingdom | N/A | ||
![]() |
Antibiotice S.A. | Romania | ATB |